Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

All Drugs and Chemicals

Estrogens

Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.

Cryoablation

This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers. The intra-tumoral and systemic immune response to cryoablation will be determined and compared to pre-ablated breast cancer specimens and historical control specimens.

Patients with small breast cancers will undergo cryoablation of their breast cancer. Approximately six weeks after cryoablation, definitive breast surgery will be performed. Blood will be drawn for research before cryoablation and surgery and at regular follow-up visits. Blood and tissue samples will be used to determine immune responses.

Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers

CHUM-CRYOABLATION: Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers

1. Determine number (percentage via flow cytometry), phenotype and functionality of tumor infiltrating lymphocytes in ablated breast cancer
2. Determine number (percentage via flow cytometry)and phenotype of APC in ablated breast cancer
3. Characterize cytokine and chemokine expression (in IU) in ablated tissue and in pre-ablated and post-ablated serum over time
4. Quantify T cell response (IUs of IL2 and IFN gamma, and T cell specific cells as measured by number of spots on an elispot assay) to tumor associated antigens using in vitro assays of T cell proliferation and function (cytokine release, elispot, peptide-MHC)
5. Determine morphology and histology of regional lymph node after cryoablation

1. Difference in intra-tumoral lymphocyte populations (percentage via flow cytometry) in ablated and non-ablated breast cancers
2. Compare serum cytokine and chemokine expression (in IU) between patients undergoing or not undergoing tumor ablation
3. Compare intra-tumoral lymphocyte populations (percentage via flow cytometry) in ablated tumor tissue with paraffin embedded specimens for tumors that are matched for age, tumor size and histology.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers	NCT01856036	Breast Cancer	Cryoablation	18 Years -	Saint John's Cancer Institute
Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers	NCT01856036	Breast Cancer	Cryoablation	18 Years -	Saint John's Cancer Institute

Spots Global Cancer Trial Database for ductal histology